Vadadustat

Unassigned

New Medicines

Anaemia in chronic kidney disease in patients not on dialysis and on dialysis

Information

New molecular entity
Otsuka
Akebia

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Hypoxia-inducible factors are transcription factors which play a key role in activating the expression of genes that control body defence mechanisms against low levels of oxygen.
UK prevalence of stage 3-5 CKD is about 8.5% (8,500 per 100,000 people). Prevalence of anaemia in CKD (defined as a haemoglobin level less than 12 g/dL in men and postmenopausal women and less than 11 g/dL in premenopausal women) is about 12% [3].
Anaemia in chronic kidney disease in patients not on dialysis and on dialysis
Oral